Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio di valutazione dell'NPT 2042 rispetto al placebo in soggetti di età compresa tra 16 e 75 anni con epilessia generalizzata genetica (GGE) e crisi di assenza

24 settembre 2026 aggiornato da: NeuroPro Therapeutics, Inc.

Uno studio crossover monocentrico, in doppio cieco, controllato con placebo per la valutazione dell'NPT 2042 rispetto al placebo in soggetti di età compresa tra 16 e 75 anni con epilessia generalizzata genetica (GGE) e convulsioni in assenza

This study will compare the effect of NPT 2042 and placebo in subjects with GGE on the frequency and duration of electroencephalographic absence seizures, separated by a 14-day washout period. The study will be a single-center, double-blind, crossover study with subjects receiving either NPT 2042 BID orally or matching placebo BID in each of two treatment periods. Two doses of NPT 2042 will be evaluated.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

14

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Arkansas
      • Little Rock, Arkansas, Stati Uniti, 77205
        • Clinical Trials, Inc. (CTI)

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 16 anni a 75 anni (Bambino, Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Subject is capable of and provides consent/assent, and the study participant's parent/legal representative/caregiver provides signed informed consent for minor study participants, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF)
  2. Subject is aged 16-75 years at the time of consent/assent
  3. Subject is diagnosed with genetic generalized epilepsy with absence seizures (consistent with the International League Against Epilepsy (ILAE) Classification of Seizures (2017))
  4. Subject has electroencephalogram (EEG) evidence of bilateral synchronous generalized paroxysmal spike-wave (2.5 Hz to 6 Hz) bursts lasting 3 seconds or more at least 4 times on the screening 72-hour ambulatory EEG.
  5. Subject has been on a stable dose of at least one antiseizure medication (ASM) for at least 30 days. Vagal nerve stimulation at stable settings (for at least 30 days before screening), without use of the magnet, is also acceptable.
  6. Subject has normal cognition and no clinically significant abnormalities on neurological examination at screening in the opinion of the Investigator
  7. Subject is in otherwise good health (with the exception of epilepsy), as determined by the investigator, and as documented in the medical history, physical examination, and screening laboratory investigations
  8. Subject has a body mass index (BMI) between 18 and 40 kg/m2 inclusive, at screening
  9. Female subjects of child-bearing potential and all men agree to use of highly effective methods of contraception during the study and for 28 days after last dose of study drug
  10. Subject (and parent/caregiver, if applicable) is able to communicate with the investigator and to understand and comply with all study requirements, including the clinic visit schedule

Exclusion Criteria:

  1. Subject has metabolic or mitochondrial encephalopathies, seizures associated with structural abnormalities, or infection-related seizures.

  2. Subject has a developmental epileptic encephalopathy (e.g. Lennox-Gastaut syndrome)

  3. Subject has a history of convulsive status epilepticus within the past year.

  4. Subject has a history of surgical intervention for treatment of epilepsy

  5. Subject has a history of nonepileptic seizures (e.g., metabolic, structural, or paroxysmal non epileptic seizures)

  6. Subject has severe intellectual disability, severe autism spectrum disorder, or severe developmental disorder such that the subject cannot consent or assent to participate or cannot cooperate with the study procedures

  7. Female subject who is pregnant or lactating

  8. Subject has any clinically significant laboratory abnormality which, in the opinion of the investigator, will exclude the subject from the study

  9. Subject has an active CNS infection, demyelinating disease, degenerative neurological disease, or any CNS disease deemed to be progressive during the course of the study that may confound the interpretation of the study results

  10. Subject has any clinically significant psychiatric illness, psychological or behavioral problems which, in the opinion of the investigator, would interfere with the subject's ability to participate in the study, including but not limited to the following:

    1. Subject has active suicidal ideation prior to study entry as indicated by a positive response ("yes") to either Question 4 or Question 5 of the Columbia Suicide Severity Rating Scale (C-SSRS)
    2. Study participant has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt)
  11. Subject is suffering from clinically significant active liver disease, porphyria or has a family history of severe hepatic dysfunction indicated by abnormal liver function tests greater than three times the upper limit of normal (AST and ALT)

  12. Subject has a DSM-V diagnosis of alcohol or drug abuse, or drug addiction within the past 12 months

  13. Subject has participated in any other trials involving an investigational product or device within 30 days of screening or longer, as required by local regulations

  14. Subject is currently using prohibited medications or products

  15. Subject is unable to complete ingestion of four placebo SGCs with a minimum of eight ounces of water at screening

  16. Subject (and parent/caregiver, if applicable) has daily commitments during the study duration that would interfere with attending all study visits

  17. Positive urine drug test for substance of abuse or illegal recreational substances at screening

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione incrociata
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: NPT 2042 80mg

NPT 2042 80mg BID

NPT 2042 is a new drug being developed as an anti-seizure treatment

Placebo Comparator

Comparatore placebo: Placebo for NPT 2042 80mg

Matching placebo for active comparator

NPT 2042 is a new drug being developed as an anti-seizure treatment

Placebo Comparator

Comparatore attivo: NPT 2042 160mg

NPT 2042 160mg BID

NPT 2042 is a new drug being developed as an anti-seizure treatment

Placebo Comparator

Comparatore placebo: Placebo for NPT 2042 160mg

Matching placebo for active comparator

NPT 2042 is a new drug being developed as an anti-seizure treatment

Placebo Comparator

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Mean and median across subjects of the within subject difference in percent change from treatment period baseline of the frequency of absence seizures
Lasso di tempo: Up to 12 weeks

Mean and median across subjects of the within subject difference in percent change from treatment period baseline of the frequency of absence seizures (defined as 2.5-6 Hz spike-wave bursts lasting greater than 3 seconds) between NPT 2042 and placebo.

Up to 12 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Mean and median across subjects of the within subject difference between NPT 2042 and placebo on absence seizures
Lasso di tempo: Up to 12 weeks

Mean and median across subjects of the within subject difference between NPT 2042 and placebo on absence seizures (defined as 2.5-6 Hz spike-wave bursts lasting greater than 3 seconds) average duration.

Up to 12 weeks
Mean and median across subjects of the within subject categorical difference in percent change between NPT 2042 and placebo of the frequency of absence seizure
Lasso di tempo: Up to 12 weeks

Mean and median across subjects of the within subject categorical difference in percent change between NPT 2042 and placebo of the frequency of absence seizure (defined as 2.5-6 Hz spike wave bursts lasting greater than 3 seconds) using the following categories:

  • 1 - < 3 seconds
  • 3 - 5 seconds
  • >5 - 10 seconds
  • >10 seconds
Up to 12 weeks
The proportion of NPT 2042- vs. placebo-treated subjects meeting the study specific response criteria
Lasso di tempo: Up to 12 weeks

The proportion of NPT 2042- vs. placebo-treated subjects meeting the following response criteria:

  • ≥50% decrease in endpoint seizure frequency compared to treatment period baseline
  • ≥75% decrease in endpoint seizure frequency compared to treatment period baseline
  • Seizure freedom
Up to 12 weeks
The mean change from Baseline across subjects of the within subject difference between NPT 2042 and placebo on the Quality of Life in Epilepsy Questionnaire (QOLIE-31-P)
Lasso di tempo: Up to 12 weeks

The mean change from Baseline across subjects of the within subject difference between NPT 2042 and placebo on the Quality of Life in Epilepsy Questionnaire (QOLIE-31-P)

Up to 12 weeks
The mean change from Baseline in the Digit Symbol Substitution Test
Lasso di tempo: Up to 12 weeks

The mean change from Baseline in the Digit Symbol Substitution Test following treatment with NPT 2042 compared to placebo

Up to 12 weeks
The mean change from Baseline in the Epworth Sleepiness Scale
Lasso di tempo: Up to 12 weeks

The mean change from Baseline in the Epworth Sleepiness Scale following treatment with NPT 2042 compared to placebo

Up to 12 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

11 marzo 2025

Completamento primario (Effettivo)

17 agosto 2026

Completamento dello studio (Effettivo)

23 settembre 2026

Date di iscrizione allo studio

Primo inviato

23 dicembre 2024

Primo inviato che soddisfa i criteri di controllo qualità

7 gennaio 2025

Primo Inserito (Effettivo)

10 gennaio 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

28 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

24 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • NPT 2042 CL-200

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .